Tyra Biosciences (NASDAQ:TYRA) Upgraded at Wall Street Zen

Key Points

• Tyra Biosciences was upgraded from a "sell" to a "hold" rating by Wall Street Zen, signaling a shift in investor sentiment.
• Analysts from HC Wainwright, Raymond James Financial, and Oppenheimer have set target prices ranging from $30.00 to $36.00 for Tyra Biosciences, indicating strong interest in the stock.
• The company recently reported ($0.47) earnings per share, exceeding analysts' expectations of ($0.53), and has a market capitalization of approximately $667.32 million.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

Several other equities analysts also recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, August 22nd. Oppenheimer reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday, September 10th. Raymond James Financial initiated coverage on shares of Tyra Biosciences in a report on Tuesday, September 2nd. They set a "strong-buy" rating and a $35.00 price objective on the stock. Finally, Piper Sandler initiated coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $31.86.

Tyra Biosciences Stock Performance

NASDAQ TYRA traded up $0.64 during mid-day trading on Friday, reaching $12.79. 192,541 shares of the stock were exchanged, compared to its average volume of 229,982. The business's 50 day moving average is $11.38 and its 200-day moving average is $10.30. Tyra Biosciences has a 1 year low of $6.42 and a 1 year high of $29.60. The company has a market capitalization of $681.71 million, a P/E ratio of -7.19 and a beta of 1.10.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.06. Equities analysts predict that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. US Bancorp DE increased its position in Tyra Biosciences by 50.5% during the first quarter. US Bancorp DE now owns 5,435 shares of the company's stock worth $51,000 after purchasing an additional 1,823 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Tyra Biosciences during the fourth quarter worth about $60,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Tyra Biosciences during the first quarter worth about $84,000. Exchange Traded Concepts LLC increased its position in Tyra Biosciences by 42.7% during the first quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company's stock worth $110,000 after purchasing an additional 3,550 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company's stock worth $126,000 after purchasing an additional 1,668 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.